Phase 2

BRIDGEWATER, N.J., July 16, 2026 Insmed Incorporated has announced positive 12-month results from the ongoing open-label extension (OLE) study...

WATERTOWN, Mass., July 16, 2026 Diagonal Therapeutics has reached a significant milestone in rare disease drug development by announcing...

CAMBRIDGE, Mass., July 14, 2026 Biogen announced positive Phase 2 CELIA study results demonstrating that investigational antisense oligonucleotide therapy...

BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 14, 2026 Hemab Therapeutics presented new clinical and preclinical data at the International...

LEXINGTON, Mass., July 6, 2026 Curis, Inc. announced an important enrollment milestone for its Phase 2 TakeAim CLL clinical...

BOSTON, July 6, 2026 CervoMed Inc. announced that new clinical findings on its investigational therapy neflamapimod will be presented...

FRAMINGHAM, Mass., July 6, 2026 Alzheon, Inc. announced that it will present nine scientific posters at the 2026 Alzheimer’s...

REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...

CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...